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www.cdatm.orgAbstractNeoadjuvant therapy has become the standard of care for locally advanced mid-low rectal cancer. Pathological complete
response (pCR) can be achieved in 12%e38% of patients. Patients with pCR have the most favorable long-term outcomes.
Intensifying neoadjuvant therapy and extending the interval between termination of neoadjuvant treatment and surgery may in-
crease the pCR rate. Growing evidence has raised the issue of whether local excision or observation rather than radical surgery is an
alternative for patients who achieve a clinical complete response after neoadjuvant therapy. Herein, we highlight many of the
advances and resultant controversies that are likely to dominate the research agenda for pCR of rectal cancer in the modern era.
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open access article under the CC BY-NC-ND license (http://creativecommmesorectal excision (TME) is curative. However, for
locally advanced low rectal cancer (T3/T4 or Nþ) with
a relatively high risk of locoregional recurrence, neo-
adjuvant therapy followed by TME has become the
standard of care in order to downstage the tumor,
thereby facilitating dissection and improving surgical
outcomes.1 Tumor regression after chemoradiotherapy
(CRT) is observed in most patients, with 12%e38%
cases showing a pathological complete response (pCR)
in postoperative specimens.2e5 The predictive factors
of pCR include the primary tumor size, histological
type, pretreatment clinical stage, neoadjuvant therapy
regimens, and interval between neoadjuvant therapy
and surgery.6e8 Achievement of pCR after neoadjuvantElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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comes and significantly decreased local recurrence
(LR) in locally advanced rectal cancer (LARC).9,10
Recently, it has been suggested that radical surgery
should be avoided in patients who achieve a clinical
complete response (cCR). Selected patients may
benefit from the management of local excision (LE) or
simple observation (“wait and see” or “wait and watch”
strategy), improving the possibility of organ preserva-
tion with comparable survival.11e14 Here, the latest
advancements in clinical research on pCR after neo-
adjuvant therapy are reviewed, focusing on current
imaging, predictive factors, prognosis and manage-
ment. We highlight many of the advances and resultant
controversies that are likely to dominate the research
agenda for pCR of rectal cancer in the modern era.
Restaging after neoadjuvant therapy for rectal
cancer
Implementation of neoadjuvant therapy requires an
accurate staging to identify patients who would benefit
from such treatment. Current imaging techniques have
been reported to be highly accurate in the primary
staging of rectal cancer. However, a neoadjuvant
therapy course induces deep modifications of cancer
tissue and surrounding structures such as fibrosis with
mucin pools, deep stroma alteration, bowel wall
thickening, muscle disarrangement, tumor necrosis,
calcification, and inflammatory infiltration. As a result,
the same imaging techniques, when used for restaging,
are much less accurate. Sensitivity, specificity, and
accuracy of computed tomography (CT), endorectal
ultrasonography (EUS), and magnetic resonance im-
aging (MRI) to preoperatively determine locoregional
neoplastic extension are suboptimal for this purpose.
The accuracy of CT in predicting T stage after a
neoadjuvant therapy course is still controversial in the
literature.15,16 CT scanning is commonly considered an
unreliable restaging technique to assess pCR.17 In a
study conducted by Huh et al18 in 80 patients, the
retrospectively analyzed CT scans were unable to
predict pCR in any patient. Restaging lymph nodes
after a neoadjuvant therapy course could also be more
complex because radiotherapy has the ability to
reshape and modify the size and texture of the nodes.
In terms of nodal involvement, CT has an accuracy of
82% by using a cutoff of 10 mm.16 On the contrary, in
a 5-mm cutoff setting, the accuracy has been reported
to be 62%.17
The assessment of rectal tumor by means of EUS is
based on the evaluation of depth of invasion throughthe five layers of the bowel wall. The accuracy of EUS
ranged from 27% to 72% in T restaging but only 0%e
60% in correctly diagnosing ypT0.19 Its accuracy in
restaging lymph nodal involvement ranged between
39% and 83%. The accuracy of EUS is insufficient in
detecting which tumors show T0N0 after neoadjuvant
treatment.
MRI currently plays a crucial role in the primary
staging of rectal cancer by guiding therapeutic man-
agement.20 The sensitivity of MRI for T stage was
87%, and its specificity was 75% in the primary stag-
ing of rectal cancer.21 Diffusion-weighted MRI, espe-
cially at high b values, would be effective for the
prediction of treatment outcome and early detection of
tumor response. The addition of diffusion-weighted
imaging to standard rectal MRI improves the selec-
tion of complete responders after chemoradiation.22,23
Dynamic contrast-enhanced magnetic resonance im-
aging is reported to have a sensitivity of 100% for
distinguishing complete and incomplete responses.24
Nodal staging by using MRI usually relies on size
criteria but was a poor predictor of nodal status. Using
5 mm (any axis) as a cutoff for an abnormally sized
lymph node has proven to provide a sensitivity of 66%
and a specificity of 76% to predict malignant
involvement.25
Management of cCR
Contemporary management of LARC involves
preoperative CRT, followed by surgery and then
adjuvant systemic chemotherapy. Despite various de-
grees of tumor response, radical resection of the pri-
mary tumor and draining lymph nodes remain the
standard recommendation. Most published studies re-
ported a favorable prognosis in patients who achieved a
pCR after neoadjuvant therapy followed by TME.9,26,27
Aggressive TME surgery is a significant associated risk
factor of morbidity, including anastomotic leakage,
pelvic automatic nerve injury, and mortality.27e32
Moreover, a proportion of patients who underwent
rectal cancer surgery will require either a temporary or
permanent stoma. It has been suggested that radical
surgery be omitted in patients with cCR, especially in
patients with distal tumors, avoiding a permanent
stoma.11,12
LE may offer the possibility of organ preservation
for the management of selected patients after neo-
adjuvant CRT. Callender et al33 reported that full-
thickness LE offers a comparable local control,
disease-free survival (DFS), and overall survival (OS)
to that achieved with proctectomy and TME. LE also
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after neoadjuvant therapy. In case of poor response or
non-pCR, a salvage TME surgery could be performed
timely.34
The non-surgical, observation-only replacement
therapy (“wait and see”) was first introduced by Habr-
Gama et al.11 In a prospectively observed cohort of
patients with a cCR, no initial surgical intervention
was performed. During almost 5 years of follow-up,
they reported LR, DFS, and OS rates comparable to
those in patients who underwent immediate low ante-
rior or abdominoperineal resection with TME. None of
the patients developed pelvic LR. The reported 5-year
DFS of 71 cCR patients was 92%, compared with the
83% for patients with radical surgery-confirmed pCR
(P ¼ 0.09). Maas et al14 proposed a strict selection
criterion for the wait-and-see policy, not only con-
firming that the oncological outcome after observation
was comparable with that in patients who achieved a
pCR after radical excision but also evaluating bowel
function. Patients who underwent observation had
better functional outcomes than those who received
surgery. The difference was larger in terms of control
over flatus and the change in bowel habits, since all the
patients with a pCR after surgery had changed bowel
habits.
Two key points need to be clarified in investigating
whether LE or “wait and see” could be a valid alter-
native to radical surgery. First, a significant correlation
was found between cCR and pCR. Hiotis et al35 per-
formed a retrospective review of the clinical and
pathological characteristics of 488 patients from the
Memorial Sloan-Kettering Prospective Colorectal
Database. This study demonstrated a 19% cCR rate
with preoperative therapy and a 10% pCR rate among
all patients. The pCR rate among the clinical complete
responders was 25%, and most (75%) of the cCR pa-
tients had persistent foci of tumor that was not
detectable on preoperative examination or colonos-
copy. Smith et al36 retrospectively assessed the
morphological and histological features of residual
tumor and found that 61.3% (19/31) of patients with a
pCR had evidence of a residual mucosal abnormality
consistent with an incomplete clinical response. Thus,
it is unreliable to predict pCR simply based on the
absence of clinically palpable or visible tumor after
neoadjuvant therapy. Second, the rate of lymph node
metastasis in ypT0 patients should be low enough.
Coco et al37 reported that the rate correlated with ypT
stage, with 1.8% for ypT0 cases and 6.3% for ypT1
cases. In a literature review, Kundel et al38 summarized
the rate of involved lymph nodes in ypT0 patients torange from 0% to 17%, with an average rate of lymph
node involvement of 5%.
Therefore, owing to the accuracy limitation, modern
imaging techniques are unreliable in restaging rectal
cancer after CRT. A negative preoperative biopsy result
after a near-complete clinical response should not be
considered sufficient for avoiding a radical resection.39
With a sensitivity of 50% and negative predictive value
of 11%, the accuracy of a simple forceps biopsy for
predicting pathological response after neoadjuvant
CRT was only 53%, which prevents the uncritical
extrapolation of LE or “wait and see” as a routine
therapeutic option for clinically proved complete re-
sponders, except in selected patients with a strong will
for sphincter-saving or could not tolerate radical sur-
gery because of poor physical condition.
Predictive factors of pCR
As patients with a pCR have better long-term out-
comes than those without a pCR, in recent years, many
trials have used pCR as a surrogate end-point for
long-term outcomes such as DFS or even OS.40
Complete regression has been reported in 12e38%
of patients.2e5,41e43 Therefore, improving the rate of
pCR is also a major task in neoadjuvant therapy for
rectal cancer. It is commonly believed that different
neoadjuvant therapeutic regimens and intervals be-
tween neoadjuvant CRT and surgery significantly
affect the pCR rate. Other factors that predict a pCR
after neoadjuvant treatment of rectal cancers include
absence of circumferential involvement and signet ring
cell histology, primary tumor size, histological type,
and pretreatment clinical stage.6e8
Neoadjuvant therapy regimen and pCR
Long-course (LC) preoperative CRT has been
widely practiced in the last two decades.27 The
Swedish Rectal Cancer Trial 3 demonstrated that short-
course (SC) preoperative radiotherapy reduced the risk
of LR by half.44 To date, only 2 randomized trials
(Polish and Australian randomized studies) have
directly compared short- and long-course therapies
with delayed surgery in resectable rectal cancer.45,46
The Polish study compared short- and long-course
preoperative pelvic radiotherapies for T3/T4 mid to
low rectal cancer, and found higher rates of pCR in
the LC (16%) than in the SC (1%) group.45 In the
Australian randomized trial for clinical stage T3
rectal cancer that compared SC radiotherapy with
LC-CRT, no differences in distant recurrence rates
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P ¼ 0.62) were found. In particular, 24 LC patients
(15%) had ypT0 (pCR) as compared with only 2
SC patients (1%).46
The administration of chemotherapy before neo-
adjuvant CRT has the theoretical advantages of
downstaging a locally advanced tumor, eliminating
micrometastatic disease, and improving tolerance
to chemotherapy when compared with its adminis-
tration in the adjuvant setting. Short-course radio-
therapy does not include administration of sensitizing
chemotherapy. Long-course radiotherapy includes
administration of sensitizing therapy, most commonly
5-fluorouracil (5-FU). Two randomized controlled
trials, EORTC 22921 and FFCD 9203, showed that the
addition of fluorouracil to radiotherapy significantly
increased the pCR rate as compared with radiotherapy
alone.47,48 Gerard et al48 compared neoadjuvant
radiotherapy plus capecitabine with dose-intensified
radiotherapy plus capecitabine and oxaliplatin in 598
randomly assigned patients and concluded that the
addition of oxaliplatin to radiotherapy did not signif-
icantly increase the tumor response rate (13.9% vs.
19.2%, P ¼ 0.09). Similar results were also obtained
in the STAR-01 trial.49 Mohiuddin et al50 reported that
even in fixed rectal cancers, continuous infusion of 5-
FU and a preoperative radiation dose of 5500 cGy or
higher could achieve a pCR rate of 44%. Further
analysis demonstrated that in patients treated with
high-dose radiation greater than 5500 cGy, a signifi-
cantly higher pCR (67%) was observed in patients
who received continuous venous infusion, but none of
the patients with bolus 5-FU achieved pCR
(P ¼ 0.017).50
In a recent study reported by Schrag et al,51 8 (25%)
of 32 patients with clinical stage II to III rectal cancer
who received 6 cycles of FOLFOX (5-FU, leucovorin,
and oxaliplatin) with bevacizumab achieved pCR. This
finding demonstrated that a neoadjuvant systemic
therapy without routine use of pelvic radiation could be
delivered without apparent compromise of either short-
or long-term outcomes in carefully staged patients with
rectal cancer.
In an attempt to increase pCR rates and reduce local
and distant recurrence, several strategies have been
evaluated, including the addition of other chemother-
apeutic agents and targeted therapies to 5-FU and ra-
diation, as well as induction chemotherapy before
concurrent CRT. Crane et al52 treated patients with
clinically staged T3N1 (n ¼ 20) or T3N0 (n ¼ 5) rectal
cancer by administering neoadjuvant therapy with
radiotherapy (50.4 Gy/28F), bevacizumab every 2weeks (3 doses of 5 mg/kg), and capecitabine (900 mg/
m2 orally twice daily only on days of radiation), fol-
lowed by TME resection. In their study, they observed
that 8 (32%) of 25 patients had a pCR, confirming the
feasibility of neoadjuvant chemotherapy with XELOX
plus bevacizumab. Dipetrillo et al53 reported treating
patients with rectal cancer by using an induction
regimen consisting of bevacizumab plus modified
infusional 5-FU, leucovorin, and oxaliplatin (FOL-
FOX6) followed by concurrent bevacizumab, oxali-
platin, continuous infusion of 5-FU and radiation. Five
(20%) of 25 patients had a pCR. The addition of
bevacizumab to neoadjuvant CRT resulted in an
encouraging pCR rate. However, these studies were
limited by the single-arm analysis design without a
control group.
Induction chemotherapy has been suggested to
affect preoperative CRT efficacy in LARC. In a ran-
domized multicenter phase II study conducted by
Marechal et al,3 patients with T2eT4/Nþ rectal
adenocarcinoma were randomly assigned to arm
Adpreoperative CRT with 5-FU continuous infusion
followed by surgerydor arm Bdinduction oxaliplatin,
folinic acid, and 5-FU followed by CRT and surgery.
No statistically significant differences in pCR (28% vs.
26%) were found. In another multicenter phase II trial,
patients in group 1 had TME 6e8 weeks after CRT.
The patients in group 2e4 received additional 2, 4, or 6
cycles of mFOLFOX6. A comparison between patients
who received 6 cycles of mFOLFOX6 and those who
received the standard neoadjuvant CRT showed a sig-
nificant difference in pCR rate (38% vs. 18%,
P ¼ 0.011). This strategy is being tested in phase III
clinical trials.54
In the FOWARC study from China, 495 patients
with rectal cancer within 12 cm from the anal verge,
clinical stage II or III, were randomly assigned to
receive 5-FU with radiotherapy (control arm), mFOL-
FOX6 with radiotherapy (FOLFOX-RT arm), or 4e6
cycles of mFOLFOX6 alone (FOLFOX arm). The pCR
rates were 12.5%, 31.3%, and 7.4% in the control,
FOLFOX-RT, and FOLFOX arms, respectively
(P ¼ 0.001). mFOLFOX6 concurrent with RT resulted
in a higher pCR rate.55
The interval between neoadjuvant therapy and
surgery
It is recommended by the National Comprehensive
Cancer Network (NCCN) guidelines that surgery
should be implemented within 5e10 weeks after
neoadjuvant therapy. During this interval, which
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patients could recover from any treatment-related
toxicity and be relieved of local acute inflammatory
response to radiotherapy. Studies have indicated that
extending the interval between CRT and surgery may
increase the proportion of patients who achieve a
pCR. Wolthuis et al56 showed a significantly higher
pCR rate after a longer interval (over 7 weeks, 28%)
than after a shorter interval (no more than 7 weeks,
16%; P ¼ 0.006). In a meta-analysis, Petrelli et al8
systematically reviewed 13 prospective or retrospec-
tive studies, including 3584 patients, and found that a
longer waiting interval (more than the classic 6e8
weeks) from the end of preoperative CRT increased
the rate of pCR by 6% in rectal cancer, without
compromising similar outcomes and complication
rates. Although longer intervals may result in favor-
able pathological findings, it is unclear whether this
translates into clinical benefits.57 In a recently pub-
lished study, compared with short interval (2 weeks),
longer interval (6e8 weeks) was significantly asso-
ciated with pCR (26% vs. 10.3%, P ¼ 0.015), but had
no impact on survival.58
Delayed surgery may induce pelvic fibrosis and
increase the technical difficulty of the operation and
the risk of surgical complications and locoregional
recurrence.59 For now, whether delayed surgery after
neoadjuvant CRT could offer clear benefits in terms of
pCR remains unclear. Grimminger et al60 suggested
that pretreatment of intratumoral epidermal growth
factor receptor (EGFR) and vascular endothelial
growth factor (VEGF) mRNA expression levels, as
well as KRAS mutation status, were predictive markers
of pathological response to neoadjuvant cetuximab-
based chemoradiation in LARC. In the future, for the
proper selection of patients who will benefit from
neoadjuvant therapy, predictive molecular markers
should be identified.
Adjuvant chemotherapy for pCR
According to the latest NCCN guideline, adjuvant
chemotherapy is recommended for all patients with
stage II/III rectal cancer who have undergone neo-
adjuvant CRT/surgery regardless of the surgical path-
ological results. However, when no viable tumor is
identified in postoperative specimens, the benefit of
adjuvant chemotherapy is much less clear. Complete
response to neoadjuvant CRT may indicate tumor
chemosensitivity and is an important biomarker of
long-term outcome.57 Geva et al61 analyzed the data of
260 patients with rectal cancer who had been treatedwith neoadjuvant chemotherapy. Of the patients, 54
were found to have achieved pCR. They suggested that
adjuvant chemotherapy played no part in the DFS and
OS of pCR patients. Kiran et al62 even challenged the
routine use of adjuvant chemotherapy for patients
whose cancers have no node involvement. At present,
the comprehensive multidisciplinary treatment strategy
for rectal cancer needs to be balanced between inade-
quate treatment and overtreatment.
Conclusion
Pathological complete response after neoadjuvant
therapy for rectal cancer is associated with signifi-
cantly improved long-term outcomes. Intensified neo-
adjuvant therapy and delayed surgery are likely to
increase the pCR rate. Owing to the limited accuracy
of clinical imaging in predicting pCR, radical surgery
remains the standard of care for patients downstaged
by neoadjuvant therapy. LE or the “wait and see”
strategy should be recommended with caution in
selected cCR patients who have a strong will for
sphincter-saving or could not tolerate radical surgery.
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